Navidea Biopharmaceuticals Inc. has filed for Chapter 11 bankruptcy under Subchapter V in the U.S. Bankruptcy Court for the District of Delaware, aiming to restructure its financial obligations while maintaining limited operations. The biopharmaceutical company, known for its precision immunodiagnostic agents and immunotherapeutics, said the move will allow it to explore strategic alternatives and protect its assets. Navidea plans to use the bankruptcy process to ensure equitable treatment of...